{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:14:59Z","timestamp":1787505299072,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}]},{"name":"Internal Funding Prioritization Committee"},{"name":"City of Hope\u2019s Womens\u2019 Cancers Program"},{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel, minimally invasive method of delivering intraperitoneal chemotherapy with promising peritoneal disease control in ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This US multicenter prospective phase I trial (NCT04329494) evaluated the safety and efficacy of PIPAC cisplatin 10.5 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and doxorubicin 2.1 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (PIPAC-CD) every 6 weeks in ovarian cancer at three US centers. Primary endpoints were dose-limiting toxicities and adverse events. Secondary endpoints included response according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria, laparoscopic peritoneal carcinomatosis index, histologic peritoneal regression grading score, progression-free survival (PFS), and overall survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 15 patients were enrolled. The median prior lines of therapy was 3 (range 1\u201310). The PIPAC completion rate (\u22652 PIPACs) was 86.7%. A total of 76.9% of patients had extraperitoneal disease at baseline. One patient discontinued treatment for toxicity because of deterioration of her baseline Eastern Cooperative Oncology Group 2 performance status. There was one grade 3 abdominal pain, one grade 3 anorexia, and no grade 4 or 5 adverse events. Laparoscopic best response (peritoneal carcinomatosis index) and histologic response (peritoneal regression grading score) occurred in 30.8% and 46.2%, respectively. Radiologic best response (RECIST) was 6.7%, with one partial response and a stable disease rate of 26.7%. Median PFS and OS were 2.3 months (95% confidence interval 1.7\u20133.2) and 17.1 months (95% confidence interval 5.6\u2013not reached), respectively (n=15).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PIPAC-CD is feasible, safe, and well tolerated at academic US centers. OS and PFS were limited in patients with heavily pretreated ovarian carcinoma who underwent PIPAC-CD. Future trials should focus on optimizing PIPAC drug combinations and determining optimal patient selection criteria for ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18432-0","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T17:48:41Z","timestamp":1759254521000},"page":"415-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Efficacy of Cisplatin and Doxorubicin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients with Ovarian Cancer with Peritoneal Metastases: A Multicenter US Phase I Trial"],"prefix":"10.1245","volume":"33","author":[{"given":"Brad","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Senguttuvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora H.","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Yost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raechelle","family":"Tinsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Synold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine","family":"Villella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Merchea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle K.","family":"DePeralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghee","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Raoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh Hue","family":"Dellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"5","key":"18432_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","volume":"4","author":"M Markman","year":"2003","unstructured":"Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4(5):277\u201383.","journal-title":"Lancet Oncol."},{"issue":"1","key":"18432_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med. 2006;354(1):34\u201343.","journal-title":"New Engl J Med."},{"issue":"26","key":"18432_CR3","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV, O\u2019Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med. 1996;335(26):1950\u20135.","journal-title":"New Engl J Med."},{"issue":"3","key":"18432_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. New Engl J Med. 2018;378(3):230\u201340.","journal-title":"New Engl J Med."},{"issue":"5","key":"18432_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100586","volume":"7","author":"P Filis","year":"2022","unstructured":"Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022;7(5):100586.","journal-title":"ESMO Open."},{"issue":"1","key":"18432_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/cancers12010034","volume":"12","author":"G Nadiradze","year":"2019","unstructured":"Nadiradze G, Horvath P, Sautkin Y, Archid R, Weinreich FJ, K\u00f6nigsrainer A, et al. Overcoming drug resistance by taking advantage of physical principles: pressurized intraperitoneal aerosol chemotherapy (PIPAC). Cancers (Basel). 2019;12(1):34.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"18432_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2015.02.009","volume":"137","author":"CB Tempfer","year":"2015","unstructured":"Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study. Gynecolc Oncol. 2015;137(2):223\u20138.","journal-title":"Gynecolc Oncol."},{"issue":"2","key":"18432_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1245\/s10434-023-14648-0","volume":"31","author":"G Vizzielli","year":"2024","unstructured":"Vizzielli G, Giudice MT, Nardelli F, Costantini B, Salutari V, Inzani FS, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) applied to platinum-resistant recurrence of ovarian tumor: a single-institution experience (ID: PARROT Trial). Ann Surg Oncol. 2024;31(2):1207\u201316.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"18432_CR9","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/cancers13051060","volume":"13","author":"M Robella","year":"2021","unstructured":"Robella M, De Simone M, Berchialla P, Argenziano M, Borsano A, Ansari S, et al. A phase I dose escalation study of oxaliplatin, cisplatin and doxorubicin applied as PIPAC in patients with peritoneal carcinomatosis. Cancers (Basel). 2021;13(5):1060.","journal-title":"Cancers (Basel)."},{"issue":"12","key":"18432_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107250","volume":"49","author":"C Taliento","year":"2023","unstructured":"Taliento C, Restaino S, Scutiero G, Arcieri M, Bernardi G, Martinello R, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: A systematic review. Eur J Surg Oncol. 2023;49(12):107250.","journal-title":"Eur J Surg Oncol."},{"key":"18432_CR11","doi-asserted-by":"publisher","first-page":"1204886","DOI":"10.3389\/fonc.2023.1204886","volume":"13","author":"A Kefleyesus","year":"2023","unstructured":"Kefleyesus A, Bhatt A, Escayola C, Khomyakov V, H\u00fcbner M, Reymond MA, et al. Descriptive review of current practices and prognostic factors in patients with ovarian cancer treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC): a multicentric, retrospective, cohort of 234 patients. Front Oncol. 2023;13:1204886.","journal-title":"Front Oncol."},{"issue":"1","key":"18432_CR12","doi-asserted-by":"publisher","first-page":"20180111","DOI":"10.1515\/pp-2018-0111","volume":"4","author":"SP Somashekhar","year":"2019","unstructured":"Somashekhar SP, Ashwin KR, Rauthan A, Rohit KC. Pressurized intraperitoneal aerosol chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial. Pleura Peritoneum. 2019;4(1):20180111.","journal-title":"Pleura Peritoneum."},{"issue":"4","key":"18432_CR13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ejso.2021.10.028","volume":"48","author":"M H\u00fcbner","year":"2022","unstructured":"H\u00fcbner M, Alyami M, Villeneuve L, Cort\u00e9s-Guiral D, Nowacki M, So J, et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. Eur J Surg Oncol. 2022;48(4):789\u201394.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"18432_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/pp-2022-0102","volume":"7","author":"O Sgarbura","year":"2022","unstructured":"Sgarbura O, Eveno C, Alyami M, Bakrin N, Guiral DC, Ceelen W, et al. Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum. 2022;7(1):1\u20137.","journal-title":"Pleura Peritoneum."},{"issue":"12","key":"18432_CR15","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1016\/j.ejso.2020.05.007","volume":"46","author":"M Alyami","year":"2020","unstructured":"Alyami M, Sgarbura O, Khomyakov V, Horvath P, Vizzielli G, So J, et al. Standardizing training for pressurized intraperitoneal aerosol chemotherapy. Eur J Surg Oncol. 2020;46(12):2270\u20135.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"18432_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.4787","volume":"3","author":"PH Frankel","year":"2020","unstructured":"Frankel PH, Chung V, Tuscano J, Siddiqi T, Sampath S, Longmate J, et al. Model of a queuing approach for patient accrual in phase 1 oncology studies. JAMA Netw Open. 2020;3(5):e204787.","journal-title":"JAMA Netw Open."},{"key":"18432_CR17","doi-asserted-by":"publisher","first-page":"1404936","DOI":"10.3389\/fonc.2024.1404936","volume":"14","author":"B Nakamura","year":"2024","unstructured":"Nakamura B, Senguttuvan R, Ruel NH, Frankel PH, Yost SE, Cole S, et al. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial. Front Oncol. 2024;14:1404936.","journal-title":"Front Oncol."},{"issue":"7","key":"18432_CR18","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368\u201377.","journal-title":"Lancet Oncol."},{"issue":"2","key":"18432_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1515\/pp-2016-0011","volume":"1","author":"W Solass","year":"2016","unstructured":"Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum. 2016;1(2):99\u2013107.","journal-title":"Pleura Peritoneum."},{"key":"18432_CR20","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/EDBK_201441","volume":"38","author":"M Nishino","year":"2018","unstructured":"Nishino M. Tumor response assessment for precision cancer therapy: response evaluation criteria in solid tumors and beyond. Am Soc Clin Oncol Educ Book. 2018;38:1019\u201329.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"4","key":"18432_CR21","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00423-022-02455-2","volume":"407","author":"C Yurttas","year":"2022","unstructured":"Yurttas C, \u00dcberr\u00fcck L, Nadiradze G, K\u00f6nigsrainer A, Horvath P. Limitations of laparoscopy to assess the peritoneal cancer index and eligibility for cytoreductive surgery with HIPEC in peritoneal metastasis. Langenbecks Arch Surg. 2022;407(4):1667\u201375.","journal-title":"Langenbecks Arch Surg."},{"issue":"1","key":"18432_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ygyno.2018.05.001","volume":"150","author":"CB Tempfer","year":"2018","unstructured":"Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol. 2018;150(1):23\u201330.","journal-title":"Gynecol Oncol."},{"issue":"9","key":"18432_CR23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/01.cad.0000176505.94175.d4","volume":"16","author":"B Royer","year":"2005","unstructured":"Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, et al. Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anti-Cancer Drugs. 2005;16(9):1009\u201316.","journal-title":"Anti-Cancer Drugs."},{"issue":"2","key":"18432_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ejso.2006.11.006","volume":"33","author":"WH Gotlieb","year":"2007","unstructured":"Gotlieb WH, Bruchim I, Ben-Baruch G, Davidson B, Zeltser A, Andersen A, et al. Doxorubicin levels in the serum and ascites of patients with ovarian cancer. Eur J Surg Oncology. 2007;33(2):213\u20135.","journal-title":"Eur J Surg Oncology."},{"issue":"1","key":"18432_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00280-024-04727-8","volume":"95","author":"T Zhang","year":"2024","unstructured":"Zhang T, Mu W, Liao CG, Hou Y, Song J, Hu W, et al. Pharmacokinetics of cisplatin in the systemic versus hyperthermic intrathoracic or intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 2024;95(1):13.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"3","key":"18432_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00280-023-04512-z","volume":"91","author":"LAW de Jong","year":"2023","unstructured":"de Jong LAW, Lambert M, van Erp NP, de Vries L, Chatelut E, Ottevanger PB. Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer Chemother Pharmacol. 2023;91(3):247\u201356.","journal-title":"Cancer Chemother Pharmacol."},{"key":"18432_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104151","volume":"82","author":"W Ceelen","year":"2022","unstructured":"Ceelen W, Sandra L, de Sande LV, Graversen M, Mortensen MB, Vermeulen A, et al. Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases. EBioMedicine. 2022;82:104151.","journal-title":"EBioMedicine."},{"issue":"1","key":"18432_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067691","volume":"13","author":"N Lang","year":"2023","unstructured":"Lang N, Diciola A, Labidi-Galy I, Ris F, Di Marco M, Mach N, et al. Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity. BMJ Open. 2023;13(1):e067691.","journal-title":"BMJ Open."},{"key":"18432_CR29","unstructured":"Dellinger T RN, Frankel PH, Yost SE, Chang S, Wang E, Villella J, Dinh T, Raoof M. A multicenter phase I study of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin with systemic nab-paclitaxel in recurrent ovarian cancer patients \u2013 Trial in progress. Pleura Peritoneum. 2024;14th PSOGI-ISSPP International congress on Peritoneal Surface Malignancies (Issue SI, 2024):2024-0031."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18432-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18432-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18432-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:08:49Z","timestamp":1765289329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18432-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["18432"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18432-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mustafa Raoof has received research funding from Exact Biosciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}